This activity is expired and is no longer available for CME credit.


Age-Related Macular Degeneration (AMD): A Closer Look at Treatment Regimens, Dosing, and Fluid Considerations

Author(s)/Faculty: Rishi P. Singh, MD; Amy Babiuch, MD; Andrew A. Moshfeghi, MD, MBA
Release Date: 1/29/2021Expiration Date: 1/28/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0
Content Type: VideoProvider:
Pinnacle clinical studies evaluating the management of neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factor (VEGF) therapies have demonstrated significant visual acuity gains. However, these same visual acuity gains are not always observed in real-world studies due to undertreatment or lack of patient adherence associated with treatment burden. The continued refinement of treatment dosing regimens and the personalized extension of treatment intervals have the potential to overcome treatment burden and undertreatment while enhancing long-term visual outcomes. Within the CME activity, experts in the field will examine intravitreal anti-VEGF therapy treatment protocols that have demonstrated improved long-term management of nAMD, assess the latest data pertaining to the optimization of treatment dosing and therapy administration, as well as discuss the association between the persistence of retinal fluid post-treatment and visual outcomes.